



The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
May 4, 2021

Therapeutic Class	Drug Name	DURB Recommendation
Multiple Sclerosis Agents		
	<i>Kesimpta (Subcutaneous) Injection</i> <i>Aubagio (Oral) Tablet</i> <i>Gilenya (Oral) Capsule</i> <i>Rebif (Subcutaneous) Injection</i>	NP/PA
Antiparkinsons Agents		
	<i>Ongentys (Oral) Capsule</i>	NP/PA
Vasodilators, Coronary		
	<i>Verquvo (Oral) Tablet</i>	NP/PA
Duchenne Muscular Dystrophy Treatments		
	<i>Viltepso (Intravenous) Injection*</i>	NP/PA (for coverage on the PADL)

*The DURB additionally recommended that Vyondys 53 be stepped through Viltepso as part of the prior authorization process; DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers' Administered Drug List